论文部分内容阅读
目的评价重组人粒细胞集落刺激因子治疗儿童急性白血病(ALL)化疗后白细胞降低的临床运用时机。方法随机选择处于缓解期的急性白血病20例,分为2组,分别在化疗后外周血WBC为1.0~2.0×109/L和(或)ANC<1.0×109/L时(治疗组)与WBC<1.0×109/L和(或)ANC<0.5×109/L时(对照组)使用粒细胞集落刺激因子,至WBC>3.0×109/L和(或)ANC>1.5×109/L时停药。观察ANC变化,粒细胞集落刺激因子使用天数,WBC恢复的天数及感染发生率。结果治疗组ANC≤0.5×109/L持续天数,达到ANC≥1.5×109/L时使用粒细胞集落刺激因子天数,及感染发生率均明显小于对照组(P<0.05)。结论急性白血病在化疗后应尽早使用粒细胞集落刺激因子,但其拐点仍需探索研究。
Objective To evaluate the clinical application of recombinant human granulocyte-colony stimulating factor in the treatment of leukopenia after chemotherapy in children with acute leukemia (ALL). Methods Twenty patients with acute leukemia were randomly selected and divided into two groups: WBC of 1.0-2.0 × 109 / L and / or ANC <1.0 × 109 / L of peripheral blood (treatment group) and WBC When granulocyte colony-stimulating factor was used at <1.0 × 109 / L and / or ANC <0.5 × 109 / L (control group) until WBC> 3.0 × 109 / L and / or ANC> 1.5 × 109 / L medicine. ANC changes were observed, the number of days of use of granulocyte colony stimulating factor, days of WBC recovery and incidence of infection. Results The duration of ANC≤0.5 × 109 / L and the days of using granulocyte colony stimulating factor in ANC≥1.5 × 109 / L were significantly lower in the treatment group than in the control group (P <0.05). Conclusions Granulocyte colony-stimulating factor should be used as soon as possible after chemotherapy in acute leukemia, but its inflexion point still needs to be explored.